Subscribe Now Subscribe Today
Abstract
Fulltext PDF
References
Research Article
 

TRAIL-mediated Cytotoxicity: Impacts of sTRAIL and vTRAIL Microvesicles



Akira Furusaki , Satoshi Jodo , Yumi Yamashita , Yoshiharu Amasaki , Tatsuya Atsumi and Takao Koike
 
ABSTRACT

Previous studies have shown that FasL-expressing cells produced nearly equal amount of soluble FasL (sFasL) and microvesicle-associated FasL (vFasL) under regular tissue culture condition. Here, we studied the ability of TRAIL-expressing cells to produce sTRAIL and vTRAIL and compared their impact on TRAIL-mediated cytotoxicity. We found that TRAIL-expressing cells produced extremely low level of vTRAIL. It indicates that the ability of TRAIL-expressing cells to produce vTRAIL but not sTRAIL is significantly different from FasL-expressing cells and that the ability to produce vTRAIL and vFasL is a property intrinsic to the protein itself. Our study also shows that the microvesicles, containing full-length TRAIL, express strong cytotoxicity against a commonly used Jurkat target cells whereas the cytotoxicity of sTRAIL was nearly undetectable. We concluded that sTRAIL is efficiently produced so much so that it can be inhibitory for the cytotoxicity expressed by the TRAIL-expressing cells. The significance of the findings is discussed.

Services
Related Articles in ASCI
Similar Articles in this Journal
Search in Google Scholar
View Citation
Report Citation

 
  How to cite this article:

Akira Furusaki , Satoshi Jodo , Yumi Yamashita , Yoshiharu Amasaki , Tatsuya Atsumi and Takao Koike , 2006. TRAIL-mediated Cytotoxicity: Impacts of sTRAIL and vTRAIL Microvesicles . Journal of Biological Sciences, 6: 150-159.

DOI: 10.3923/jbs.2006.150.159

URL: https://scialert.net/abstract/?doi=jbs.2006.150.159

REFERENCES
Andreola, G., L. Rivoltini, C. Castelli, V. Huber and P. Perego et al., 2002. Induction of lymphocyte apoptosis by tumor cell secretion of FasL bearing microvesicles. J. Exp. Med., 195: 1303-1316.
PubMed  |  

Ashkenazi, A. and V.M. Dixit, 1998. Death receptors signaling and modulation. Science, 281: 1305-1308.
PubMed  |  

Ashkenazi, A., R.C. Pai, S. Fong, S. Leung and D.A. Lawrence et al., 1999. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 104: 155-162.
PubMed  |  

Blott, E.J., G. Bossi, R. Clark, M. Zvelebil and G.M. Griffiths, 2001. Fas ligand is targeted to secretory lysosomes via a proline rich domain in its cytoplasmic tail. J. Cell. Sci., 114: 2405-2416.
Direct Link  |  

Bonavida, B., C.P. Ng, A. Jazirehi, G. Schiller and Y. Mizutani, 1999. Selectivity of TRAIL mediated apoptosis of cancer cells and synergy with drugs the trail to non toxic cancer therapeutics (review). Intl. J. Oncol., 15: 793-802.
Direct Link  |  

Chuntharapai, A., K. Dodge, K. Grimmer, K. Schroeder and K.J. Kim et al., 2001. Isotype dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol., 166: 4891-4898.
PubMed  |  

Fanger, N.A. C.R. Maliszewski, K. Schooley and T.S. Griffith, 1999. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor related apoptosis inducing ligand (TRAIL). J. Exp. Med., 190: 1155-1164.

French, L.E. and J. Tschopp, 1999. The TRAIL to selective tumor death. Natl. Med., 5: 146-147.
Direct Link  |  

Gibson, S.B., R. Oyer, A.C. Spalding, S.M. Anderson and G.L. Johnson, 2000. Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL. Mol. Cell Biol., 20: 205-212.
PubMed  |  

Gliniak, B. and T. Le, 1999. Tumor necrosis factor related apoptosis inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT 11. Cancer Res., 59: 6153-6158.
PubMed  |  

Griffith, T.S., C.T. Rauch, P.J. Smolak, J.Y. Waugh and M.Z. Kubin et al., 1999. Functional analysis of TRAIL receptors using monoclonal antibodies. J. Immunol., 162: 2597-2605.

Griffith, T.S., S.R. Wiley, M.Z. Kubin, L.M. Sedger, C.R. Maliszewski and N.A. Fanger, 1999. Monocyte mediated tumoricidal activity via the tumor necrosis factor related cytokine TRAIL. J. Exp. Med., 189: 1343-1354.
Direct Link  |  

Griffith, T.S., W.A. Chin, G.C. Jackson, D.H. Lynch and M.Z. Kubin, 1998. Intracellular regulation of TRAIL induced apoptosis in human melanoma cells. J. Immunol., 161: 2833-2840.
Direct Link  |  

Hilliard, B., A. Wilmen, C. Seidel, T.S. Liu, R. Goke and Y. Chen, 2001. Roles of TNF related apoptosis inducing ligand in experimental autoimmune encephalomyelitis. J. Immunol., 166: 1314-1319.
PubMed  |  

Ichikawa, K., W. Liu, L. Zhao, Z. Wang, D. Liu and T. Ohtsuka et al., 2001. Tumoricidal activity of a novel anti human DR5 monoclonal antibody without hepatocyte cytotoxicity. Natl. Med., 7: 954-960.
CrossRef  |  

Jeremias, I., C. Kupatt, B. Baumann, I. Herr, T. Wirth and K.M. Debatin, 1998. Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood, 91: 4624-4631.
PubMed  |  

Jodo, S., A.M. Hohlbaum, S. Xiao, D. Chan and S.T. Ju et al., 2000. CD95 (Fas) ligand expressing vesicles display antibody mediated FcR dependent enhancement of cytotoxicity. J. Immunol., 165: 5487-5494.

Jodo, S., D. Strehlow and S.T. Ju, 2000. Bioactivities of Fas ligand expressing retroviral particles. J. Immunol., 164: 5062-5069.

Jodo, S., S. Xiao, A. Hohlbaum, D. Strehlow, A.M. Rothstein and S.T. Ju, 2001. Apoptosis inducing membrane vesicles a novel agent with unique properties. J. Biol. Chem., 276: 39938-39944.

Ju, S.T., N.H. Ruddle, P. Strack, M.E. Dorf and R.H.D. Kruyff, 1990. Expression of two distinct cytolytic mechanisms among murine CD4 subsets. J. Immunol., 144: 23-31.
PubMed  |  

Kayagaki, N., N. Yamaguchi, M. Nakayama, A. Kawasaki, H. Akiba, K. Okumura and H. Yagita, 1999. Involvement of TNF related apoptosis inducing ligand in human CD4+ T cell mediated cytotoxicity. J. Immunol., 162: 2639-2647.
Direct Link  |  

Kayagaki, N., N. Yamaguchi, M. Nakayama, H. Eto, K. Okumura and H. Yagita, 1999. Type I interferons (IFNs) regulate tumor necrosis factor related apoptosis inducing ligand (TRAIL) expression on human T cells a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med., 189: 1451-1460.
PubMed  |  

Kayagaki, N., N. Yamaguchi, M. Nakayama, K. Takeda and H. Akiba et al., 1999. Expression and function of TNF related apoptosis inducing ligand on murine activated NK cells. J. Immunol., 163: 1906-1913.
Direct Link  |  

Liu, S., Y. Yu, M. Zhang, W. Wang and X. Cao, 2001. The involvement of TNF alpha related apoptosis inducing ligand in the enhanced cytotoxicity of IFN beta stimulated human dendritic cells to tumor cells. J. Immunol., 166: 5407-5415.
PubMed  |  

Lorenzo, M.J.M., A. Anel, S. Gamen, I. Monlen, P. Lasierra and L. Larrad et al., 1999. Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol., 163: 1274-1281.
PubMed  |  

Lorenzo, M.J.M., M.A. Alava, S. Gamen, K.J. Kim and A. Anel et al., 1998. Involvement of APO2 ligand TRAIL in activation induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol., 28: 2714-2725.
PubMed  |  

M.J. Smyth, E. Cretney, K. Takeda, R.H. Wiltrout and K. Okumura et al., 2001. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) contributes to interferon gamma dependent natural killer cell protection from tumor metastasis. J. Exp. Med., 193: 661-670.

Mariani, S.M. and P.H. Krammer, 1998. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol., 28: 973-982.

Miller, A.D., D.G. Miller, J.V. Garcia and C. M. Lynch, 1993. Use of retroviral vectors for gene transfer and expression. Methods Enzymol., 217: 581-599.

Monleon, I., M.J.M. Lorenzo, L. Monteagudo, P. Lasierra and M. Taules et al., 2001. Differential secretion of fas ligand or Apo2 ligand TNF related apoptosis inducing ligand carrying microvesicles during activation induced death of human Tcells. J. Immunol., 167: 6736-6744.

Mori, S., K. Murakami-Mori, S. Nakamura, A. Ashkenazi and B. Bonavida, 1999. Sensitization of AIDS aposi's sarcoma cells to Apo ligand nduced apoptosis by actinomycin D. J. Immunol., 162: 5616-5623.
Direct Link  |  

Nagata, S., 1997. Apoptosis by death factor. Cell, 88: 355-365.
CrossRef  |  

Pan, G., K. O'Rourke, A.M. Chinnaiyan, R. Gentz, R. Ebner, J. Ni and V.M. Dixit, 1997. The receptor for the cytotoxic ligand TRAIL. Science, 276: 111-113.
PubMed  |  

Phillips, T.A., J. Ni, G. Pan, S.M. Ruben, Y.F. Wei, J.L. Pace and J.S. Hunt, 1999. TRAIL (Apo 2L) and TRAIL receptors in human placentas implications for immune privilege. J. Immunol., 162: 6053-6059.

Pitti, R.M., S.A. Marsters, S. Ruppert, C.J. Donahue, A. Moore and A. Ashkenazi, 1996. Induction of apoptosis by Apo 2 ligand a new member of the tumor necrosis factor cytokine family. J. Biol. Chem., 271: 12687-12690.
PubMed  |  

Schneider, P., M. Thome, K. Burns, J.L. Bodmer and J. Tschopp et al., 1997. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD dependent apoptosis and activate NF kappa B. Immunity, 7: 831-836.
PubMed  |  

Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana and J. Tschopp, 1998. Conversion of membrane bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med., 187: 1205-1213.
PubMed  |  

Screaton, G.R., J. Mongkolsapaya, X.N. Xu, A.E. Cowper, A.J. McMichael and J.I. Bell, 1997. TRICK2 a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr. Biol., 7: 693-696.
PubMed  |  

Sedger, L.M., D.M. Shows, R.A. Blanton, J.J. Peschon, R.G. Goodwin, D. Cosman and S.R. Wiley, 1999. IFN gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. J. Immunol., 163: 920-926.

Smyth, M.J., K. Takeda, Y. Hayakawa, J.J. Peschon, M.R.V. Brink and H. Yagita, 2003. Nature's TRAIL on a path to cancer immunotherapy. Immunity, 18: 1-6.
PubMed  |  

Snell, V., K. Clodi, S. Zhao, R. Goodwin, E.K. Thomas and S.W. Morris et al., 1997. Activity of TNF related apoptosis inducing ligand (TRAIL) in haematological malignancies. Br. J. Haematol., 99: 618-624.
Direct Link  |  

Song, K., Y. Chen, R. Goke, A. Wilmen, C. Seidel, A. Goke and B. Hilliard, 2000. Tumor necrosis factor related apoptosis inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression. J. Exp. Med., 191: 1095-1104.
PubMed  |  

Sprick, M.R., M.A. Weigand, E. Rieser, C.T. Rauch and P. Juo et al., 2000. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by Immunity, 12: 599-609.
PubMed  |  

Strehlow, D., S. Jodo and S.T. Ju, 2000. Retroviral membrane display of apoptotic effector molecules. Proc. Natl. Acad. Sci. USA., 97: 4209-4214.
PubMed  |  

Suda, T., H. Hashimoto, M. Tanaka, T. Ochi and S. Nagata, 1997. Membrane Fas ligand kills human peripheral blood T lymphocytes and soluble Fas ligand blocks the killing. J. Exp. Med., 186: 2045-2050.
Direct Link  |  

Takeda, K., M.J. Smyth, E. Cretney, Y. Hayakawa, N. Kayagaki, H. Yagita and K. Okumura, 2002. Critical role for tumor necrosis factor related apoptosis inducing ligand in immune surveillance against tumor development. J. Exp. Med., 195: 161-169.

Takeda, K., Y. Hayakawa, M.J. Smyth, N. Kayagaki and K. Okumura et al., 2001. Involvement of tumor necrosis factor related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Natl. Med., 7: 94-100.

Tanaka, M., T. Itai, M. Adachi and S. Nagata, 1998. Downregulation of Fas ligand by shedding. Natl. Med., 4: 31-36.
CrossRef  |  

Thomas, W.D. and P. Hersey, 1998. TNF related apoptosis inducing ligand (TRAIL) induces apoptosis in Fas ligand resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol., 161: 2195-2200.
PubMed  |  

Trabzuni, D., K.S. Famulski and M. Ahmad, 2000. Functional analysis of tumour necrosis factor alpha related apoptosis inducing ligand (TRAIL) cysteine 30 plays a critical role in the homotrimerization and biological activity of this novel tumoricidal cytokine. Biochem. J., 350: 505-510.
Direct Link  |  

Vidalain, P.O., O. Azocar, B. Lamouille, A. Astier, C.R. Combe and C.S. Delprat, 2000. Measles virus induces functional TRAIL production by human dendritic cells. J. Virol., 74: 556-559.
Direct Link  |  

Walczak, H., M.A.D. Esposti, R.S. Johnson, P.J. Smolak and J.Y. Wanugh et al., 1997. TRAIL R2 a novel apoptosis mediating receptor for TRAIL. Embo. J., 16: 5386-5397.
PubMed  |  

Walczak, H., R.E. Miller, K. Ariail, B. Gliniak and T.S. Griffith et al., 1999. Tumoricidal activity of tumor necrosis factor related apoptosis inducing ligand In vivo. Natl. Med., 5: 157-163.
PubMed  |  

Widom, R.L., I. Culic, J.Y. Lee and J.H. Korn, 1997. Cloning and characterization of hcKrox a transcriptional regulator of extracellular matrix gene expression. Gene, 198: 407-420.
CrossRef  |  

Wiley, S.R., K. Schooley, P.J. Smolak, W.S. Din and C.P. Huang et al. 1995. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 3: 673-682.
PubMed  |  

Xiao, S., U.S. Deshmukh, S. Jodo, T. Koike and S.T. Ju et al., 2004. Novel negative regulator of expression in Fas ligand (CD178) cytoplasmic tail evidence for translational regulation and against Fas ligand retention in secretory lysosomes. J. Immunol., 173: 5095-5102.
Direct Link  |  

Zamai, L., M. Ahmad, I.M. Bennett, L. Azzoni, E.S. Alnemri and B. Perussia, 1998. Natural Killer (NK) cell mediated cytotoxicity differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med., 188: 2375-2380.

©  2019 Science Alert. All Rights Reserved
Fulltext PDF References Abstract